(Q28207989)

English

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

scientific article (publication date: 15 July 2001)

In more languages

Statements

scholarly article

0 references

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation (English)

0 references

stem cell transplantation

1 reference

based on heuristic

inferred from title

author name string

F J Giles

1

0 references

H M Kantarjian

2

0 references

S M Kornblau

3

0 references

D A Thomas

4

0 references

G Garcia-Manero

5

0 references

T A Waddelow

6

0 references

C L David

7

0 references

A T Phan

8

0 references

D E Colburn

9

0 references

A Rashid

10

0 references

E H Estey

11

0 references

language of work or name

0 references

publication date

15 July 2001

0 references

0 references

92

0 references

2

0 references

406-13

0 references

Veno-occlusive disease of the liver

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncolog

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Veno-occlusive disease of the liver in children following chemotherapy for acute myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Hepatic veno-occlusive disease caused by 6-thioguanine

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

6-thioguanine as a cause of toxic veno-occlusive disease of the liver

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Actinomycin D associated hepatic veno-occlusive disease--a report of 2 cases

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Veno-occlusive disease of the liver associated with thiopurines in a child with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Antibody therapy of acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

MR imaging findings in two patients with hepatic veno-occlusive disease following bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Solution structure of the calicheamicin gamma 1I-DNA complex

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

DNA bending is a determinant of calicheamicin target recognition

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Supercoiling affects the accessibility of glutathione to DNA-bound molecules: positive supercoiling inhibits calicheamicin-induced DNA damage.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Exclusive production of bistranded DNA damage by calicheamicin.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010715%2992%3A2%3C406%3A%3AAID-CNCR1336%3E3.0.CO%3B2-U

21 January 2018

Identifiers

10.1002/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28207989&oldid=1500693636"